Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Improving the in vivo persistence, distribution and function of cytotoxic T lymphocytes by inhibiting the tumor immunosuppressive microenvironment.

Xu W, Cai J, Li S, Zhang H, Han J, Wen M, Wen J, Gao F.

Scand J Immunol. 2013 Jul;78(1):50-60. doi: 10.1111/sji.12065.

2.
3.

Effector cells derived from naive T cells used in tumor immunotherapy of mice bearing B16 melanoma.

Wen M, Xu W, Ren L, Gao F, Cui N, Wen J, Li X, Lin L, Ma Z, Chen B, Cai J.

Chin Med J (Engl). 2014;127(7):1328-33.

PMID:
24709189
4.

Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.

Rubinstein MP, Cloud CA, Garrett TE, Moore CJ, Schwartz KM, Johnson CB, Craig DH, Salem ML, Paulos CM, Cole DJ.

J Am Coll Surg. 2012 Apr;214(4):700-7; discussion 707-8. doi: 10.1016/j.jamcollsurg.2011.12.034. Epub 2012 Feb 22.

5.

Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.

Proietti E, Greco G, Garrone B, Baccarini S, Mauri C, Venditti M, Carlei D, Belardelli F.

J Clin Invest. 1998 Jan 15;101(2):429-41.

7.
8.

Adoptive transfer of cytotoxic T-cells for treatment of residual disease after irradiation.

Krause M, Schmitz M, Noessner E, Skrablin PS, Wehner R, Rieber EP, Baumann M.

Int J Radiat Biol. 2007 Nov-Dec;83(11-12):827-36.

PMID:
17852560
9.
11.

Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.

Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH, Sayers TJ.

J Immunol. 2002 Apr 1;168(7):3484-92.

13.

Reduced tumorigenesis of EG7 after interleukin-10 gene transfer and enhanced efficacy in combination with intratumorally injection of adenovirus-mediated lymphotactin and the underlying mechanism.

Zhang J, Zhou Z, Wang C, Shen J, Zheng Y, Zhang L, Wang J, Xia D.

Cancer Immunol Immunother. 2011 Apr;60(4):559-73. doi: 10.1007/s00262-010-0955-5. Epub 2011 Jan 15.

PMID:
21240488
14.

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.

Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ.

J Exp Med. 1996 Jan 1;183(1):87-97.

15.

Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.

Maas RA, Roest PA, Becker MJ, Weimar IS, Dullens HF, Den Otter W.

Immunobiology. 1992 Nov;186(3-4):214-29.

PMID:
1490728
16.

In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model.

Du X, Jin R, Ning N, Li L, Wang Q, Liang W, Liu J, Xu Y.

Oncol Rep. 2012 Nov;28(5):1743-9. doi: 10.3892/or.2012.2013. Epub 2012 Sep 3.

PMID:
22948809
17.
18.

Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice.

Verra NC, Jorritsma A, Weijer K, Ruizendaal JJ, Voordouw A, Weder P, Hooijberg E, Schumacher TN, Haanen JB, Spits H, Luiten RM.

Cancer Res. 2004 Mar 15;64(6):2153-61.

19.

Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.

Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I, Baccarini S, Maccari S, Ramoni C, Belardelli F, Proietti E.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):644-53.

20.

Effective adoptive transfer of haploidentical tumor-specific T cells in B16-melanoma bearing mice.

Cui NP, Xie SJ, Han JS, Ma ZF, Chen BP, Cai JH.

Chin Med J (Engl). 2012 Mar;125(5):794-800.

PMID:
22490577

Supplemental Content

Support Center